Well, revenue is not recurring, but it has been consistently growing since 2016 (the earning part has had some up and downs though).
Canaccord predicts the NPAT of 2021 and 2022 to be in the order of 18M. With the interim report (EBITDA=12 which means roughly an NPAT in the order of 10), we are in track for that.
This means that we are dealing with a growth company with a P/E of 9. I don't know how lumpy the earnings are going to be, but this seems like a very good risk-reward to me (in a growing sector).
- Forums
- ASX - By Stock
- AVA
- Ann: Ava Group Achieves Record Result for H1 FY2021 (unaudited)
Ann: Ava Group Achieves Record Result for H1 FY2021 (unaudited), page-22
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVA (ASX) to my watchlist
|
|||||
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.39M |
Open | High | Low | Value | Volume |
11.0¢ | 11.0¢ | 10.5¢ | $9.635K | 89.68K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 294113 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 81015 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 294113 | 0.105 |
16 | 377990 | 0.100 |
1 | 30000 | 0.097 |
2 | 114582 | 0.096 |
3 | 107078 | 0.095 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 81015 | 5 |
0.120 | 66853 | 5 |
0.125 | 46739 | 2 |
0.130 | 220522 | 6 |
0.135 | 309001 | 5 |
Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
Featured News
AVA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online